Table 1.
Demographic, disease, and treatment characteristics.
| Characteristic | R-M (N = 53) | OBS (N = 84) | p |
|---|---|---|---|
| Age at diagnosis, mean(SD) | 60.5 (12.8) | 61.4 (12.1) | 0.684 |
| Female, n (%) | 27 (50.9) | 45 (53.6) | 0.861 |
| Race, n (%) | 0.193 | ||
| Non-White | 4 (7.5) | 9 (10.7) | |
| White | 49 (92.5) | 70 (83.3) | |
| Unknown | 0 (0) | 5 (6) | |
| Primary insurance, n (%) | 0.232 | ||
| Public | 19 (35.8) | 36 (42.9) | |
| Private | 34 (64.2) | 47 (56) | |
| Other/unknown | 0 (0) | 1 (1.2) | |
| Disease stage at diagnosis, n (%) | 0.350 | ||
| I-II | 9 (17) | 24 (28.6) | |
| III-IV | 40 (75.5) | 49 (58.3) | |
| Unknown/other | 4 (7.5) | 11 (13.1) | |
| ECOG performance status, n (%) | 0.300 | ||
| 0 | 18 (34) | 19 (22.6) | |
| 1 | 4 (7.5) | 8 (9.5) | |
| 2 | 0 (0) | 2 (2.4) | |
| Missing | 31 (58.5) | 55 (65.5) | |
| FLIPI class, n (%) | 0.111 | ||
| Low risk (0-1) | 17 (32.1) | 23 (27.4) | |
| Intermediate risk (2) | 7 (13.2) | 24 (28.6) | |
| High risk (3-5) | 29 (54.7) | 37 (44) | |
| Front-line therapy*, n (%) | 0.05 | ||
| Rituximab monotherapy | 18 (33.96) | 18 (21.43) | |
| Chemotherapy without rituximab | 1 (1.9) | 10 (11.9) | |
| Chemotherapy with rituximab | 34 (64.2) | 56 (66.7) | |
| Start date of front-line therapy, mean (SD, days) | 12/9/2005 (532) | 10/8/2004 (1188) | 0.005 |
| Duration (days) of frontline therapy, mean (SD) | 104.2 (67.1) | 108.4 (56.7) | 0.693 |
| Duration (days) of R-M or OBS†, median (SE) | 448 (107.4) | 1336 (320.0) |
*
Collapsed to rituximab containing therapy versus non-rituximab-containing therapy for comparison.
†
Kaplan-Meier used to estimate median and standard error including censored observations. Duration of R-M and OBS were not compared statistically because by definition the R-M group duration was constrained by having to be on maintenance therapy.
R-M, rituximab maintenance; OBS, observation; ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index.